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Abstract
AIM
To reveal better diagnostic markers for differentiating 
neuroendocrine tumor (NET) from solid-pseudopapillary 
neoplasm (SPN), focusing primarily on immunohistochemical 
analysis.
METHODS
We reviewed 30 pancreatic surgical specimens of 
NET (24 cases) and SPN (6 cases). We carried out 
comprehensive immunohistochemical profiling using 
9 markers: Synaptophysin, chromogranin A, pan-
cytokeratin, E-cadherin, progesterone receptor, 
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vimentin, α-1-antitrypsin, CD10, and β-catenin.
RESULTS
E-cadherin staining in NETs, and nuclear labeling of 
β-catenin in SPNs were the most sensitive and specific 
markers. Dot-like staining of chromogranin A might 
indicate the possibility of SPNs rather than NETs. 
The other six markers were not useful because their 
expression overlapped widely between NETs and SPNs. 
Moreover, two cases that had been initially diagnosed 
as NETs on the basis of their morphological features, 
demonstrated SPN-like immunohistochemical profiles. 
Careful diagnosis is crucial as we actually found two 
confusing cases showing disagreement between the 
tumor morphology and immunohistochemical profiles.
CONCLUSION
E-cadherin, chromogranin A, and β-catenin were the 
most useful markers which should be employed for 
differentiating between NET and SPN.
Key words: Neuroendocrine tumor; Pancreas; Solid-
pseudopapillary neoplasm; Immunohistochemistry; 
Diagnosis
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Neuroendocrine tumor (NET) and solid-
pseudopapillary neoplasm (SPN) are two types of 
pancreatic tumor that were sometimes confused in 
differential diagnosis. We reviewed 30 pancreatic 
surgical specimens of NET (24 cases) and SPN (6 cases). 
We carried out comprehensive immunohistochemical 
profiling using 9 markers. E-cadherin staining in NETs, 
and nuclear labeling of β-catenin in SPNs were the 
most sensitive and specific markers. Dot-like staining 
of chromogranin A might indicate the possibility of 
SPNs rather than NETs. Moreover, two cases that 
had been initially diagnosed as NETs on the basis of 
their morphological features, demonstrated SPN-like 
immunohistochemical profiles.
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INTRODUCTION
Neuroendocrine tumor (NET) and solid-pseudopapillary 
neoplasm (SPN) of the pancreas differ from each 
other significantly in terms of tumor aggressiveness, 
treatment, and prognosis. NETs are considered to 
have malignant potential, as 40%-90% of them 
(excluding insulinoma) show gross invasive growth 
or metastasis[1,2], whereas SPNs have low grade 
malignancy, exhibiting local invasion or metastasis 
in only 20% of cases[3]. Consequently, the five-year 
survival rate for patients with NETs is worse than 
that for patients with SPNs (65% of NETs vs 95% of 
SPNs)[3,4]. Surgical resection is the mainstay treatment 
for both types of tumor, irrespective of whether 
they are localized or metastatic. For patients with 
unresectable NET, chemotherapy using agents such 
as somatostatin analogues, α-interferon, sunitinib, or 
mTOR inhibitor can be applied[5,6]. On the other hand, 
clinical trials have yet to yield an effective form of 
chemotherapy for unresectable SPNs[7]. Due to these 
differences in clinical features and strategies, careful 
differentiation between NETs and SPNs is needed, as 
this can have a crucial bearing on outcome.
Morphological structures have often been the 
key guide for differentiating SPNs from NETs. SPNs 
have a distinctive appearance, exhibiting solid and 
pseudopapillary growth patterns. Grossly, they appear 
as a large encapsulated mass, containing yellowish 
solid areas, with cystic zones that are frequently 
necrotic or hemorrhagic[8]. Microscopically, this hete-
rogeneous growth pattern demonstrates solid areas 
with alternating pseudopapillary structures, together 
with cystic spaces made up of poorly cohesive mono-
morphic cells with abundant degenerative changes[9,10]. 
However, SPNs can show considerable morphological 
overlap with NETs. That is, a proportion of NET cases 
may show cystic and necrotic areas composed of 
discohesive cells, and a proportion of SPN cases may 
show a predominantly solid growth pattern without 
pseudopapillary structures[9,11]. In a review of a case 
series, Liu et al[12] reported that three of 14 NETs had 
cystic components, whereas one of 10 SPNs did not 
exhibit cystic areas. Accordingly, it was not possible 
to distinguish these two types of tumor simply on the 
basis of their gross or microscopic features.
In addition to morphological evaluation, im-
munohistochemical analysis plays a crucial role 
in differentiating these two tumor types. Klimstra 
et al[13,14] have reported a simple algorithm for 
diagnostic evaluation of pancreatic neoplasms, and 
demonstrated that immunohistochemstry based on 
the direction of tumor differentiation can be useful 
for establishment of tumor entities. Basturk et al[15] 
reviewed earlier reports indicating that synaptophysin, 
chromogranin A, pan-cytokeratin, and E-cadherin were 
markers for NETs, whereas progesterone receptor, 
vimentin, α-1-antitrypsin, CD10, and nuclear labeling 
of β-catenin were markers for SPNs. However, the 
expressions of these markers show overlap between 
NETs and SPNs[12,16,17]. For example, synaptophysin, 
a neuroendocrine marker expressed in most NETs, 
is also expressed in a number of SPNs[18,19]. As the 
sensitivity and specificity of the markers used in earlier 
studies have varied, more practical procedures for 
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correct diagnosis are anticipated.
In the present study, we reviewed the morphological 
and immunohistochemical profiles of 30 pancreatic 
tumors including 24 cases of NET and 6 cases of 
SPN. We comprehensively surveyed the usefulness 
of 9 markers in order to derive better diagnostic 
procedures for differentiating between the two tumor 
types. As a result, we discovered two confusing cases 
which showed both NET-like morphology and SPN-like 
immunohistochemical profiles, indicating the difficulties 
in differential diagnosis.
MATERIALS AND METHODS
Patients and tissue samples
Surgical specimens of primary NETs (24 cases) and 
SPNs (6 cases) of the pancreas were obtained at 
the Department of Surgery, University of Tsukuba 
Hospital, Tsukuba, Japan, between 2002 and 2011. All 
of the patients provided informed consent for analysis 
of their tissue samples in accordance with the ethics 
committee of University of Tsukuba Hospital. The 
specimens had been originally diagnosed by at least 
two pathologists in accordance with the World Health 
Organization (WHO) classification[10,20]. The grading of 
the NETs was re-evaluated on the basis of the WHO 
classification 2010, using the mitotic count and Ki-67 
labeling index. Cases of Grade 1 and Grade 2 NET 
were included in the present study, but Grade 3 cases 
(neuroendocrine carcinoma) were excluded.
Immunohistochemical procedures
We performed immunohistochemical staining for 
synaptophysin, chromogranin A, pan-cytokeratin, 
E-cadherin, progesterone receptor, vimentin, α-1-
antitrypsin, CD10, β-catenin, and Ki-67. Briefly, 
the resected tissues were fixed in 10% formalin 
and embedded in paraffin blocks, and the most 
representative block was chosen for each case. 
Each block was cut into serial sections 2 μm thick, 
and then deparaffinized with xylene and rehydrated 
with ethanol. After antigen retrieval and blocking 
of endogenous peroxidase activity with hydrogen 
peroxide, the sections were incubated with the primary 
antibodies (listed in Table 1, along with the antigen 
retrieval methods, dilutions, and incubation methods). 
All antigens except for progesterone receptor were 
detected using the EnVision+ System-HRP (Dako 
Japan, Tokyo, Japan); progesterone receptor was 
detected using an ultraView DAB universal kit (Roche 
Diagnostics, Tokyo, Japan). After visualization with 
diaminobenzidine chromogen, the sections were 
counterstained with hematoxylin, dehydrated with 
ethanol, made transparent with xylene, and mounted. 
All specimens were also stained with hematoxylin and 
eosin (H&E).
Interpretation of immunohistochemical staining and 
morphological features
Synaptophysin, chromogranin A, pan-cytokeratin, 
E-cadherin, vimentin, and α-1-antitrypsin were 
assessed for membranous and/or cytoplasmic staining. 
For progesterone receptor and β-catenin staining, 
nuclear labeling was evaluated as positive expression. 
All immunohistochemical markers except for Ki-67 
were classified as strongly positive (++), weakly 
positive (+), or negative (-). Briefly, the distribution (no 
stain: 0-1%, focal: 2%-50%, or diffuse: 51%-100%) 
and the intensity (weak or strong) of cells in the 
stained sections were determined separately. Diffuse 
distribution with strong intensity was evaluated as 
strongly positive. Diffuse-weak, focal-strong or focal-
weak combinations were all evaluated as weakly 
positive. No stain was evaluated as negative. For Ki-67 
staining, nuclear labeling index of Ki-67 per 500-2000 
cells was counted. Mitotic count was evaluated in at 
least 50 high-power fields using HE staining. Gross 
morphologic features were evaluated by analyzing 
pictures of the resected tumors and H&E-stained 
sections.
RESULTS
Clinicopathological and morphological characteristics
The clinicopathological data for the examined cases 
are listed in Table 2. Postoperatively, 24 cases had 
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Table 1  Immunohistochemical procedures
Antigen (Clone) Manufacturer Antigen retrieval Dilution Incubation
solution/temperature/time temperature/time
Synaptophysin (27G12) Nichirei Biosciences, Tokyo, Japan TB/105 ℃/10 min Prediluted RT/30 min 
Chromogranin A (polyclonal) Dako Japan, Tokyo, Japan CB/115 ℃/10 min   1:500 RT/30 min 
Pan-cytokeratin (AE1/AE3) Dako Japan, Tokyo, Japan TB/105 ℃/10 min   1:100 RT/30 min 
E-cadherin (36B5) Thermo Scientific, Yokohama, Japan TB/121 ℃/10 min 1:20 RT/60 min 
Progesterone receptor (IE2) Roche Diagnostics, Tokyo, Japan CB/115 ℃/10 min Prediluted RT/30 min 
Vimentin (V9) Dako Japan, Tokyo, Japan CB/100 ℃/15 min   1:100 RT/30 min 
α-1-antitrypsin (polyclonal) Dako Japan, Tokyo, Japan No retrieval   1:100 RT/30 min 
CD10 (56C6) Leica Microsystems, Tokyo, Japan TB/105 ℃/10 min 1:40 RT/30 min 
β-catenin (β-Catenin-1) Dako Japan, Tokyo, Japan TB/105 ℃/10 min   1:200 RT/30 min 
Ki-67 (MIB-1) Dako Japan, Tokyo, Japan CB/100 ℃/30 min 1:25    4 ℃/overnight 
TB: Tris-HCl buffer; CB: Citrate buffer; RT: Room temperature. 
Ohara Y et al . Diagnosis of NET and SPN
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mitosis or Ki-67 labeling of cells was scarcely evident 
in the sections. At the end of 2012, metastasis and/
or recurrence were found in 6 cases of NETs (NET-2, 
NET-3, NET-15, NET-20, NET-21, and NET-22), whereas 
they did not occur in SPN cases. Metastatic or recurrent 
NETs were treated by reoperation, chemotherapy and/
or radiotherapy after initial operation.
In the NET group, 20 cases showed a predominantly 
solid growth pattern, and 4 cases had cystic areas. 
In the SPN group, all 6 cases showed a solid and 
cystic growth pattern. The cystic lesions of SPNs 
were typically larger than those of NETs. NETs were 
composed of relatively uniform cells forming various 
organoid histological patterns, characterized by 
nesting, trabecular, glandular, gyriform, tubuloacinar, 
or pseudorosette arrangements. All of the cases in the 
SPN group showed pseudopapillary structures with 
poorly cohesive cells, whereas no such features were 
evident in the NET group.
Immunohistochemical findings
The immunohistochemical profiles are summarized 
in Table 3. Synaptophysin was positive in all NETs 
(100%), whereas in 4 SPNs (67%). Chromogranin A 
been originally diagnosed as NET (NET-1 to NET-24), 
and 6 as SPN (SPN-1 to SPN-6). The mean age of the 
patients was 54 (range 31-77) years in the NET group, 
and 28.8 (range 20-43) years in the SPN group. In 
the NET group, 11 patients were male and 13 were 
female, whereas in the SPN group one was male and 
5 were female. In the NET group, 4 cases (NET-1 to 
NET-4) were clinically diagnosed as multiple endocrine 
neoplasia type 1 (MEN1), 6 (NET-5 to NET-10) were 
diagnosed as insulinoma with clinical symptoms (e.g., 
hypoglycemia), and the other 14 (NET-11 to NET-24) 
did not have any genetic background, symptoms 
or blood examination data attributable to hormone 
hypersecretion. Preoperative enhanced computed 
tomography were performed in all cases, most of NET 
cases showed the enhancement of tumor in early 
phase, but SPN cases did not. Preoperative biopsy 
using ultrasonography was not performed in all cases. 
The mean tumor diameter of the surgical specimens 
was 3.0 (range 0.5-16) cm in the NET group, and 7.4 
(range 3.8-13) cm in the SPN group. Assessment of 
tumor grading of NETs according to the mitotic count 
and Ki-67 labeling index showed that 19 cases were 
Grade 1, and 5 were Grade 2. In the SPN group, 
Table 2  Clinicopathological and morphological characteristics of neuroendocrine tumor (24 cases) and solid-pseudopapillary 
neoplasm (6 cases)
Case Age Sex Clinical findings Tumor location Operation Diameter (cm) Mitotic Ki-67 Grade Solid or PP
(yr) count (%) for NETs Cystic pattern
NET-1 31 F MEN1 H PD      4.5 0 0 1 Solid and Cystic Absent
NET-2 57 F MEN1 H, T EC, DP      5.3 0 1 1 Solid Absent
NET-3 51 F MEN1 H, B, T, L EC, DP, LR      6.0 0 0 1 Solid Absent
NET-4 45 F MEN1 B, T DP      1.4 0 0 1 Solid and Cystic Absent
NET-5 42 F insulinoma B EC      1.0 0 0 1 Solid Absent
NET-6 62 F insulinoma H EC      1.2 0 0 1 Solid Absent
NET-7 73 M insulinoma H PD      1.5 0 0 1 Solid Absent
NET-8 74 F insulinoma T DP      1.0 0 0 1 Solid Absent
NET-9 67 M insulinoma B EC      0.9 1 0 1 Solid Absent
NET-10 51 F insulinoma B MP      1.1 7 2 2 Solid Absent
NET-11 45 M H EC      2.3 0 0 1 Solid Absent
NET-12 68 F H EC      0.5 0 0 1 Solid Absent
NET-13 77 M T DP      0.9 1 0 1 Solid Absent
NET-14 57 M H PD      1.5 1 0 1 Solid Absent
NET-15 45 M H EC      0.9 2 0 1 Solid Absent
NET-16 51 F H PD      2.5 0 1 1 Solid Absent
NET-17 59 M H MP      1.8 1 1 1 Solid Absent
NET-18 59 F T EC      2.3 1 1 1 Solid and Cystic Absent
NET-19 40 F T DP      3.3 0 4 2 Solid and Cystic Absent
NET-20 53 M T DP      5.5 2 3 2 Solid Absent
NET-21 39 M H, B, T TP 16 3 0 2 Solid Absent
NET-22 51 M H PD      7.0 7 4 2 Solid Absent
NET-23 58 F B EC      1.8 1 0 1 Solid Absent
NET-24 32 M H PD      2.3 0 0 1 Solid Absent
SPN-1 26 F H EC      8.5 0 0 - Solid and Cystic Present
SPN-2 34 F T DP      7.0 1 1 - Solid and Cystic Present
SPN-3 20 F T DP      7.5 0 0 - Solid and Cystic Present
SPN-4 23 F T DP 13 0 0 - Solid and Cystic Present
SPN-5 43 F B MP      3.8 0 0 - Solid and Cystic Present
SPN-6 27 M T DP      4.3 0 0 - Solid and Cystic Present
NET: Neuroendocrine tumor; SPN: Solid-pseudopapillary neoplasm; MEN: Multiple endocrine neoplasia; H: Pancreatic head; B: Pancreatic body; T: 
Pancreatic tail; L: Liver; PD: Pancreatoduodenectomy; MP: Middle pancreatectomy; DP: Distal pancreatectomy: TP: Total pancreatectomy; EC: Enucleation; 
LR: Liver resection; PP: Pattern pseudopapillary pattern; -: Not assessed.
Ohara Y et al . Diagnosis of NET and SPN
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was positive in all NETs (100%); however, two cases 
(NET-23 and NET-24) showed a dot-like pattern, 
whereas 22 cases showed diffuse staining. On the 
other hand, all SPNs (100%) showed a dot-like pattern 
of chromogranin A immunostaining. Pan-cytokeratin 
was positive in 20 NETs (83%), but in only one (17%) 
of the SPNs. E-cadherin was positive in 22 NETs 
(92%), with the exception of NET-23 and NET-24, 
whereas all the SPNs were negative for E-cadherin. 
Progesterone receptor, vimentin, α-1-antitrypsin, 
CD10, and β-catenin (nuclear/cytoplasmic expression) 
were positive in all SPNs (100%), whereas among the 
NETs, progesterone receptor was positive in 20 (83%), 
vimentin was positive in 10 (42%), α-1-antitrypsin was 
positive in 14 (58%), CD10 was positive in 8 (33%), 
and β-catenin was positive in 2 (8%).
The majority of NETs were positive for synapto-
physin, chromogranin A, pan-cytokeratin, E-cadherin, 
and progesterone receptor. Some cases of NET were 
positive for vimentin, α-1-antitrypsin, CD10, and 
β-catenin. On the other hand, all SPNs showed the 
same immunohistochemical profiles, being positive 
for progesterone receptor, vimentin, α-1-antitrypsin, 
CD10, and β-catenin. Moreover, they were also 
negative for E-cadherin, and showed a dot-like pattern 
of chromogranin A immunostaining. In the NET 
group we examined two cases (NET-23 and NET-24) 
that showed distinctive expression in comparison 
with the others; although these cases had been 
originally diagnosed as NETs, they showed the same 
profiles as SPNs (positive for progesterone receptor, 
vimentin, α-1-antitrypsin, CD10 and β-catenin, a 
dot-like chromogranin A pattern, and negative for 
E-cadherin). Microscopically, these cases did not show 
a pseudopapillary pattern. Representative staining 
patterns in a typical case of NET (NET-21), confusing 
case (NET-24), and a typical case of SPN (SPN-5) are 
shown in Figure 1.
DISCUSSION
Differentiating between pancreatic NETs and SPNs 
is crucial but still challenging even with precise 
morphological and histological analysis. Several 
immunohistochemical markers are reported to be 
useful for the differential diagnosis; however, not 
all of these markers are conclusive. Our immuno-
histochemical review of surgical specimens of 
NETs and SPNs demonstrated that E-cadherin, and 
nuclear labeling of β-catenin were the most sensitive 
and specific among the examined markers for 
differentiating the two type of tumors.
Table 3  Immunohistochemical profiles of neuroendocrine tumor and solid-pseudopapillary neoplasm
Case Syn CgA CK E-cad PgR Vim αATP CD10 βcat (N/C)
NET-1 ++ ++ ++ ++ - - + ++ -
NET-2 ++ ++ ++ ++ ++ - + ++ -
NET-3 ++ ++ ++ ++ ++ - ++ ++ -
NET-4 ++ ++ ++ ++ ++ ++ - - -
NET-5 ++ ++ + ++ ++ - - - -
NET-6 ++ ++ + ++ ++ - - - -
NET-7 ++ ++ ++ ++ ++ - ++ - -
NET-8 ++ ++ + ++ ++ - ++ - -
NET-9 ++ ++ - ++ - - - - -
NET-10 ++ ++ + ++ ++ ++ ++ - -
NET-11 ++ ++ - ++ ++ - + - -
NET-12 ++ ++ + + ++ ++ - - -
NET-13 ++ ++ ++ ++ ++ ++ - - -
NET-14 ++ ++ ++ ++ - ++ ++ - -
NET-15 ++ ++ ++ ++ ++ - - - -
NET-16 ++ ++ + + ++ - ++ ++ -
NET-17 ++ ++ ++ ++ ++ - - ++ -
NET-18 ++ ++ ++ ++ ++ ++ - ++ -
NET-19 ++ ++ ++ ++ ++ ++ - - -
NET-20 ++ ++ ++ ++ ++ ++ ++ - -
NET-21 ++ ++ ++ ++ ++ - ++ - -
NET-22 ++ ++ ++ ++ - - ++ - -
NET-23 ++ + (dot) - - ++ ++ ++ ++ ++
NET-24 ++ + (dot) - - ++ ++ ++ ++ ++
SPN-1 - + (dot) - - ++ ++ ++ ++ ++
SPN-2 - + (dot) - - ++ ++ ++ ++ ++
SPN-3 ++ + (dot) + - ++ ++ ++ ++ ++
SPN-4 ++ + (dot) - - ++ ++ ++ ++ ++
SPN-5 ++ + (dot) - - ++ ++ ++ ++ ++
SPN-6 ++ + (dot) - - ++ ++ ++ ++ ++
NET: Neuroendocrine tumor; SPN: Solid-pseudopapillary neoplasm; Syn: Synaptophysin; CgA: Chromogranin A; CK: Pan-cytokeratin; E-cad: E-cadherin; 
PgR: Progesterone receptor; Vim: Vimentin; αATP: α-1-antitrypsin; βcat (N/C): β-catenin (nuclear/cytoplasmic staining); ++: Strongly positive; +: Weakly 
positive; -: Negative; dot: Dot-like pattern.
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Figure 1  Macroscopic features and representative staining of a typical case of neuroendocrine tumor (case NET-21: A, D, G, J, M), a confusing case (case 
NET-24: B, E, H, K, N), and a typical case of solid-pseudopapillary neoplasm (case SPN-5: C, F, I, L, O). The typical NET case showed a solid growth pattern 
(A) with homogeneous cells, being strongly positive for chromogranin A and E-cadherin, and did not show nuclear labeling of β-catenin. In contrast, the typical SPN 
case showed a solid and cystic growth pattern (C) containing pseudopapillary structures formed by poorly cohesive cells, with a dot-like pattern of chromogranin 
A, negativity for E-cadherin, and nuclear labeling for β-catenin. NET-24, originally diagnosed as NET, mimicked the macroscopic features of NET, but exhibited the 
same immunohistochemical profile as SPN. HE, hematoxylin and eosin stain. Asterisk, cystic lesion of SPN case. Scale bars, 1 cm (macroscopic image) and 100 μm 
(microscopic image). Small boxes indicate representative magnified fields.
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As earlier studies suggested, NETs in our case 
series also showed more malignant potential and 
needed various postoperative treatments compared 
with SPNs; therefore, differential diagnosis of the two 
tumors should be performed carefully. The key gross 
and microscopic features for differential diagnosis 
between NETs and SPNs are that SPNs typically show 
a mixture of solid and cystic growth areas composed 
of pseudopapillary structures, as was the case in all 
the SPNs we examined, whereas NETs generally show 
a solid growth pattern without pseudopapillae (Table 
2). However, it should be noted that NETs sometimes 
show areas of cystic degeneration (NET-1, NET-4, 
NET-18 and NET-19). Clinical characteristics other 
than histopathology may sometimes be helpful for 
differential diagnosis between NETs and SPNs (Table 
2). Clinical symptoms may be key feature of NETs, as 
some are associated with hypersecretion of hormones 
including insulin, glucagon, somatostatin, or gastrin[21]. 
Genetic background, such as MEN1, or von Hippel-
Lindau disease, may also suggest a high likelihood 
of NET[22]. Although these features play a substantial 
role in differential diagnosis, their usefulness may 
sometimes be limited, and in fact in the present 
series of 24 NET cases diagnosis on this basis was 
made in only 10, including 4 cases of MEN1 (NET-1 to 
NET-4) and 6 cases of functional insulinoma (NET-5 to 
NET-10). The other 14 NET cases (NET-11 to NET-24) 
required further detailed differential diagnosis on the 
basis of pathology. Although SPNs occur predominantly 
in young female patients, this is not always pathogno-
monic, since males can also be sometimes affected[23], 
as was the case for SPN-6. Thus, more objective 
diagnostic modalities need to be developed.
Here we addressed the usefulness of immu-
nohistochemical expression of various markers, 
either alone or in combination, for differential 
diagnosis between NETs and SPNs. Synaptophysin 
and chromogranin A, which are representative well-
known neuroendocrine markers, were usually strongly 
positive in the majority of NETs. However, these are 
not specific markers for NETs, as 4 of the 6 SPNs we 
examined were also positive for synaptophysin, as 
reported earlier[18]. In contrast, chromogranin A has 
been regarded as typically negative in SPNs[16,18]. 
Here we found that all SPNs were weakly positive for 
chromogranin A, and that its distribution was quite 
unique, exhibiting a dot-like pattern formed by a 
relatively small number of chromogranin granules. 
Jirásek et al[24] have suggested that this expression 
of chromogranin A might reflect weak differentiation 
from a neuroendocrine lineage. In fact several 
studies have reported positivity for chromogranin 
A in SPNs[12,17,25]; these cases might be resulted in 
the criteria that dot-like pattern was evaluated as 
positive expression of chromogranin A. E-cadherin, 
a major epithelial adhesion molecule, was generally 
expressed in the majority of NETs, whereas it was 
not expressed in SPNs[26]. Loss of E-cadherin may 
explain the histological characteristics of SPNs, which 
show a pseudopapillary pattern perhaps resulting 
from loss of cell cohesiveness. Abnormal accumulation 
of β-catenin in the nucleus, caused by prolonged 
degradation of mutated β-catenin protein correlated 
with loss of E-cadherin, was observed in 95% of 
SPNs[27], whereas NET was generally negative (except 
for cases NET-23 and NET-24, as discussed in the next 
paragraph). Progesterone receptor, vimentin, α-1-
antitrypsin, and CD10, also known to be markers for 
SPNs, were expressed in all of the SPNs we examined, 
but were less specific. Therefore, the main message 
of our present study is that membranous/cytoplasmic 
expression of E-cadherin in NETs, and nuclear staining 
for β-catenin in SPNs were useful immunohistochemical 
markers, which should be routinely applied to the 
differential diagnosis between NETs and SPNs. In 
addition, chromogranin A immunostaining should 
be interpreted carefully since a dot like pattern of 
chromogranin A might indicate the possibility of SPNs 
rather than NETs.
The two confusing cases in this series (NET-23 
and NET-24) had been initially diagnosed as NETs 
because they did not show the typical morphological 
structure of SPN, i.e., solid and cystic growth and a 
pseudopapillary pattern. However, they expressed 
SPN-like immunohistochemical profiles. The issue 
here is whether these two cases were truly NETs or 
truly SPNs. The WHO classification already states that 
a few SPNs display a solid growth pattern and lack 
pseudopapillary structures[9,10], and recommends that 
immunohistochemistry including nuclear β-catenin 
staining is potentially helpful for diagnosis of these 
SPNs. Moreover, hyaline globules, which are an 
architectural feature known to occur predominantly in 
SPNs rather than in NETs[28], were actually observed 
in all 6 of the present cases of SPN. Cases NET-23 
and NET-24 also exhibited hyaline globules (data not 
shown), in addition to nuclear β-catenin staining. 
Therefore, we consider that these two cases might be 
SPNs lacking pseudopapillary structures which had 
been initially diagnosed as NETs.
The limitation of our study is that the number 
of cases we evaluated was small because SPN is 
rare pancreatic tumor. However, our present data 
should be useful for improving our routine diagnostic 
approach for NETs. In our institution, NETs have 
been initially diagnosed on the basis of gross and 
microscopic features, followed by supplementary 
immunohistochemistry for neuroendocrine markers 
including synaptophysin and chromogranin A. How-
ever, application of only neuroendocrine markers to 
“morphologically” NET-like cases is insufficient, since 
a substantial proportion of SPN cases mimicking the 
morphology of NETs will be present among these 
NET-like cases. Therefore, we propose that the 
immunohistochemical analysis should be extended to 
SPN-specific markers such as β-catenin, even if the 
tumors appear to have a NET-like morphology.
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In conclusion, we have carried out comprehensive 
immunohistochemical profiling of 24 cases of NET 
and 6 cases of SPN of the pancreas. E-cadherin and 
β-catenin are the most useful immunostaining markers 
for differentiating between NETs and SPNs. On the 
other hand, we also found two cases which showed 
disagreement between the tumor morphology and 
immunohistochemical profiles. These cases strongly 
indicate the careful and precise assessments are 
crucial for differential diagnosis between NETs and 
SPNs.
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